MATANO, ELIDE
 Distribuzione geografica
Continente #
NA - Nord America 625
EU - Europa 611
AS - Asia 108
AF - Africa 18
SA - Sud America 2
Totale 1.364
Nazione #
US - Stati Uniti d'America 616
IT - Italia 362
NL - Olanda 82
CN - Cina 81
UA - Ucraina 50
SE - Svezia 31
FI - Finlandia 21
DE - Germania 20
CI - Costa d'Avorio 18
FR - Francia 14
IE - Irlanda 11
GB - Regno Unito 10
IN - India 10
VN - Vietnam 10
CA - Canada 9
HK - Hong Kong 4
IR - Iran 3
PT - Portogallo 3
AR - Argentina 2
BE - Belgio 2
CZ - Repubblica Ceca 2
GR - Grecia 1
RO - Romania 1
SI - Slovenia 1
Totale 1.364
Città #
Chandler 121
Amsterdam 82
Ashburn 50
Napoli 44
Millbury 41
Naples 36
Princeton 25
Jacksonville 22
Beijing 21
Nanjing 20
Milan 19
San Giovanni Rotondo 19
Wilmington 12
Boston 11
Des Moines 9
Dong Ket 8
Lawrence 8
Rome 8
Arezzo 7
Ottawa 7
Ann Arbor 6
Rozzano 6
Shenyang 6
Villaricca 6
Falls Church 5
Jiaxing 5
Nanchang 5
Pune 5
Tianjin 5
Menfi 4
Salerno 4
Washington 4
Woodbridge 4
Boardman 3
Caserta 3
Changsha 3
Dublin 3
Florence 3
Hebei 3
Hong Kong 3
Leawood 3
Menlo Park 3
Redwood City 3
Serravalle Scrivia 3
Taizhou 3
Alges 2
Ardabil 2
Ballykisteen 2
Bergamo 2
Castellammare Di Stabia 2
Cipolletti 2
Courcelles 2
Fairfield 2
Frankfurt am Main 2
Frattamaggiore 2
Genova 2
Grumo Nevano 2
Hanoi 2
Houston 2
Kunming 2
Latina 2
Los Angeles 2
Mariano Comense 2
Mugnano Di Napoli 2
Nola 2
Ottaviano 2
Piove Di Sacco 2
Pregnana Milanese 2
Rapolla 2
Scafati 2
Seattle 2
Suri 2
Toronto 2
Torre Annunziata 2
Venezia 2
Andover 1
Arzano 1
Aversa 1
Bangalore 1
Bari 1
Battipaglia 1
Benevento 1
Bozen 1
Caivano 1
Cambridge 1
Capena 1
Castelvetrano 1
Catania 1
Cava De' Tirreni 1
Cesano 1
Cesenatico 1
Darmstadt 1
Duncan 1
Ercolano 1
Ferrara 1
Formia 1
Galati 1
Gambatesa 1
Genoa 1
Giugliano In Campania 1
Totale 756
Nome #
null 223
Manuale di Oncologia Clinica 95
null 67
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 49
Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report 48
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 46
A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy 46
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 40
Chlorambucil, Vincristine and Cytarabine (COA) treatment of low grade lymphomas 38
Type 2 Deiodinase Thr92Ala Polymorphism and Aging Are Associated with a Decreased Pituitary Sensitivity to Thyroid Hormone 36
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 36
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 36
Efficacy of rituximab in gastric diffuse large B cell Lymphoma patients. 33
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 32
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 32
New Therapeutic Strategies in the Treatment of Stomal Recurrence After Total Laryngectomy: Role of Immunotherapy 30
High-dose recombinant interleukin-2/verapamil combination in advanced cancer. 29
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review 29
Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4. 29
Impact of COVID-19 pandemic on 2-[18F]FDG PET/CT imaging work-flow in a single medical institution: comparison among the three Italian waves 29
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy 28
Core curriculum. Oncologia clinica 27
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. 26
Germ cell tumors in male patients without gonadal involvement: computed tomography/magnetic resonance imaging findings and diagnostic workflow 26
Brain metastases unresponsive to immunotherapy detected by 18F-FDG-PET/CT in a patient with melanoma 26
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. 25
Imatinib mesylate in thymic epithelial malignancies. 25
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 24
Phase I clinical trial of high dose recombinant interleukin-2/veparimil combination in advancer cancer. 24
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 23
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study 23
: Low dose dopamine induces early recovery of recombinant Interleukin-2 impaired renal function. 22
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). 21
Cardiovascular monitoring of drug-resistant lymphoma patients treated with EPOCH chemotherapy plus high dose verapamil in continuous infusion. 21
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. 21
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. 19
Tailored therapy for aggressive non-Hodgkin’s lymphoma: results of a phase II study with a long-term follow-up. 18
Core curriculum. Oncologia clinica 18
Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy 13
Coefficient of variation in metastatic lymph nodes determined by 18F-FDG PET/CT in patients with advanced NSCLC: combination with coefficient of variation in primary tumors 3
Totale 1.436
Categoria #
all - tutte 5.160
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.160


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 0 0 0 0 0 0 0 8 13
2019/2020157 35 10 9 7 9 6 5 6 6 17 22 25
2020/2021169 6 8 25 12 13 25 15 6 27 5 17 10
2021/2022253 9 1 3 1 4 7 9 7 11 35 65 101
2022/2023359 34 22 14 25 41 30 0 26 68 77 16 6
2023/2024223 12 41 27 21 31 40 7 27 6 8 3 0
Totale 1.436